Trial Profile
A multicentric, single blind, parallel, randomized, phase-III study to evaluate the immunogenicity and safety of BEs combined pentavalent DTwP-rHepB-HIB liquid vaccine administered to 6-8 week old healthy Indian subjects at 6-10-14 weeks EPI schedule in comparison with marketed Shan5 vaccine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2019
Price :
$35
*
At a glance
- Drugs Hib-DTP-hepatitis B vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors Biological E Limited
- 21 Jun 2010 New trial record